FOLH1 and cancer: Positron emission tomography (PET) combined with computed tomography (CT) or magnetic resonance imaging (MRI) can help to localize suspicious lesions in the prostate gland by using several prostate-specific radiotracers (i.e., Choline—labelled with either 18F and 11C, 18F-Fluciclovine, and prostate specific membrane antigen-PSMA ligands labelled with 68Ga or 18F), thus providing a valuable tool for the detection of cancer, and for the initial staging of disease [6,7].